Terns Pharmaceuticals, Inc. - Common Stock (TERN)

Competitors to Terns Pharmaceuticals, Inc. - Common Stock (TERN)

Akero Therapeutics, Inc. 

Akero Therapeutics develops treatments geared towards liver diseases, focusing notably on NASH with a unique therapeutic approach. The two companies compete for the same patient population but have different technologies and mechanisms of action. Akero's competitive advantage lies in its strong clinical results and investor interest, providing them with robust financial backing and a clear pathway to potential treatments that Terns must match.

Galectin Therapeutics, Inc. 

Galectin Therapeutics also focuses on developing therapeutic options for liver diseases, particularly targeting fibrosis and NASH. By exploring unique mechanisms of action, they aim to differentiate their treatments from those of Terns Pharmaceuticals. However, Galectin holds a smaller presence in terms of clinical validation, which may limit its competitive edge compared to Terns and others already progressing through late-stage trials.

Hepion Pharmaceuticals, Inc. 

Hepion Pharmaceuticals is another player targeting NASH and other liver diseases, employing an innovative approach with its lead candidate. Like Terns, Hepion is engaged in clinical trials aimed at efficacy and safety but faces challenges in establishing the same level of recognition and funding as some of its more advanced competitors. While launches and partnerships can shift the competitive landscape, Terns currently seems to be ahead by capitalizing on strategic collaborations.

Madrigal Pharmaceuticals, Inc. 

Madrigal Pharmaceuticals focuses on developing therapies for patients with nonalcoholic steatohepatitis (NASH) and related conditions, similar to Terns Pharmaceuticals. Both companies are in the race to innovate treatments that target liver diseases, competing for clinical trial insights and potential market share. Madrigal benefits from a more advanced clinical stage with its lead product, which puts them in a stronger position to attract partnerships and investment, thus establishing a competitive advantage in the field.